• +1-646-491-9876
    • +91-20-67278686

    Search

    Colitis - Pipeline Review, H1 2017

    Colitis - Pipeline Review, H1 2017

    • Report Code ID: RW0001689377
    • Category Healthcare
    • No. of Pages 94
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H1 2017, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

    Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 18 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively.

    Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
    - The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Colitis - Overview
    Colitis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Colitis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Colitis - Companies Involved in Therapeutics Development
    Akebia Therapeutics Inc
    Bristol-Myers Squibb Company
    Concenter BioPharma Silkim Ltd
    Cosmo Pharmaceuticals NV
    CSA Biotechnologies LLC
    Dr. Falk Pharma GmbH
    EA Pharma Co Ltd
    Genfit SA
    Immuron Ltd
    Innate Pharma SA
    Ogeda SA
    Peptinov SAS
    Pfizer Inc
    RDD Pharma Ltd
    Saniona AB
    Sigmoid Pharma Ltd
    Soligenix Inc
    Synovo GmbH
    Colitis - Drug Profiles
    AcTMP-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AKB-6899 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AN-346 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antibody for Colitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APY-0201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BC-1215 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BMS-986104 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    budesonide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CSA-13 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CSY-0073 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dimethyloxalylglycine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dusquetide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    elafibranor - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ESN-601 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMM-124E - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IPH-33 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NK-007 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PF-06425090 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PPV-06 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RDD-2007 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rifamycin CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RP-182 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Colitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Crohn's Disease and Colitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptides to Inhibit Panx1 for Colitis and Inflammatory Bowel Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TPC-1022 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target IL12 and IL23 for Colitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target IL23 for Colitis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Colitis - Dormant Projects
    Colitis - Discontinued Products
    Colitis - Product Development Milestones
    Featured News & Press Releases
    Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Colitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Colitis - Pipeline by Akebia Therapeutics Inc, H1 2017
    Colitis - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Colitis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2017
    Colitis - Pipeline by Cosmo Pharmaceuticals NV, H1 2017
    Colitis - Pipeline by CSA Biotechnologies LLC, H1 2017
    Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2017
    Colitis - Pipeline by EA Pharma Co Ltd, H1 2017
    Colitis - Pipeline by Genfit SA, H1 2017
    Colitis - Pipeline by Immuron Ltd, H1 2017
    Colitis - Pipeline by Innate Pharma SA, H1 2017
    Colitis - Pipeline by Ogeda SA, H1 2017
    Colitis - Pipeline by Peptinov SAS, H1 2017
    Colitis - Pipeline by Pfizer Inc, H1 2017
    Colitis - Pipeline by RDD Pharma Ltd, H1 2017
    Colitis - Pipeline by Saniona AB, H1 2017
    Colitis - Pipeline by Sigmoid Pharma Ltd, H1 2017
    Colitis - Pipeline by Soligenix Inc, H1 2017
    Colitis - Pipeline by Synovo GmbH, H1 2017
    Colitis - Dormant Projects, H1 2017
    Colitis - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Colitis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Colitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Akebia Therapeutics Inc
    Bristol-Myers Squibb Company
    Concenter BioPharma Silkim Ltd
    Cosmo Pharmaceuticals NV
    CSA Biotechnologies LLC
    Dr. Falk Pharma GmbH
    EA Pharma Co Ltd
    Genfit SA
    Immuron Ltd
    Innate Pharma SA
    Ogeda SA
    Peptinov SAS
    Pfizer Inc
    RDD Pharma Ltd
    Saniona AB
    Sigmoid Pharma Ltd
    Soligenix Inc
    Synovo GmbH

    Request for Sample

    Report Url https://www.reportsweb.com//colitis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//colitis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//colitis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments